Quantcast
Home > Quotes > IONS

Ionis Pharmaceuticals, Inc. Common Stock (IONS) Quote & Summary Data

IONS 
$47.91
*  
0.63
1.33%
Get IONS Alerts
*Delayed - data as of Apr. 1, 2020 14:09 ET  -  Find a broker to begin trading IONS now
Exchange:NASDAQ
Industry: Health Care
View:    IONS Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 47.85 / $ 47.95
1 Year Target
64
Today's High / Low
$ 49.105 / $ 45.1161
Share Volume
457,257
50 Day Avg. Daily Volume
1,045,859
Previous Close
$ 47.28
52 Week High / Low
$ 86.582 / $ 39.32
Market Cap
6,670,020,618
P/E Ratio
23.14
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ 2.07
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1

Intraday Chart

Shares Traded

Share Volume:
457,257
50 Day Avg. Daily Volume:
1,045,859

P/E Ratio

P/E Ratio:
23.14
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ 2.07

Trading Range

The current last sale of $47.91 is 21.85% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 49.105 $ 86.582
 Low: $ 45.1161 $ 39.32

Company Description (as filed with the SEC)

We are a leader in discovering and developing RNA-targeted therapeutics. We have created an efficient and broadly applicable drug discovery platform leveraging our expertise in antisense oligonucleotide therapeutics that we believe has fundamentally changed medicine and transformed the lives of people with devastating diseases. Our large, diverse and advancing pipeline has over 40 potential first-in-class and/or best-in-class medicines designed to address a broad spectrum of therapeutic areas, such as neurodegenerative diseases, cardiometabolic diseases, cancer and others. The medicines in our pipeline address patients with diseases ranging from rare to common. In 2019, we achieved important goals across our business, including advancing four new medicines into pivotal studies. We also reported positive clinical proof-of-concept results from five medicines, four of which were LICA medicines.  ... More ...  



Risk Grade

Where does IONS fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 45.56
Open Date:
Apr. 1, 2020
Close Price:
$ 47.28
Close Date:
Mar. 31, 2020


Consensus Recommendation

Analyst Info